Breaking News

Antibiotic Research UK launches £200,000 research grant programme

Antibiotic Research UK (ANTRUK) has launched its 2021 Small research Grants/Career Development Awards scheme, the charity’s largest grants programme to date, to tackle antibiotic resistance.

The charity will be awarding one grant of up to £50,000 and six grants of up to £25,000 each, with the monies applied for being spread over one, two or three years.

Professor Colin Garner, Chief Executive of ANTRUK, said: “These grants will fund essential research in both basic and applied sciences to help prevent another global pandemic, this time caused by antibiotic resistant bacteria.

“Supporting UK university academics in their research into antibiotics and antibiotic resistance is a key objective for ANTRUK, and we are delighted that the 2021 grants will be the largest yet for the Charity. We will offer up to seven research grants to fund projects that will help save modern medicine through better antibiotic use and stewardship.”

Grants should focus on antibiotic resistance, new antibiotic therapies, health and societal impact of antibiotic resistance, or antibiotic stewardship. The charity has said that researchers who can provide matched funding should also apply.

The grants are only available to applicants working in higher education, not-for-profit institutes, and non-governmental organisations based in the United Kingdom.

All applications will be reviewed by independent external assessors as well as by members of the Charity’s Science or Education Committees. ANTRUK has said that they have adopted the scoring system developed by the Medical Research Council for use by independent referees, and the top scoring applications will be shortlisted and then prioritised by the Charity’s Grants Panel.

ANTRUK is the world’s first charity and only charity focused on tackling bacterial antibiotic resistance. The charity’s mission is to develop new antibiotic treatments, educate the public about resistance and provide patient support.

Kat Jenkins 

This is a syndicated feed from Pharmafile

Leave a Reply

Your email address will not be published. Required fields are marked *